Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Telix Pharmaceuticals (Innovations) Pty Limited
Apollomics Inc.
Bayer
Cambridge University Hospitals NHS Foundation Trust